23 / 28
Page 58
conferenceseries
.com
Volume 08
Journal of Alzheimers Disease & Parkinsonism
Alzheimer's Congress 2018
May 30-31, 2018
May 30-31, 2018 Osaka, Japan
10
th
World Congress on
Alzheimer's Disease & Dementia
Identification of novel ApoE4 inhibitor for alzheimer’s disease therapy
Muhammad Asif Rasheed
COMSATS Institute of Information Technology, Pakistan
A
poE4 is a major genetic risk factor due to its increase incidence of developing alzheimer’s disease. The study was designed
to predict such compounds that may helpful in designing drug to suppress the over activity of apoE4 protein. 22 natural
compounds (marine, microorganism and plant derivative) were used as inhibitors and docked with apoE4 (PDB id 1B68).
6 Synthetic compounds (in clinical trials) were docked with target protein to compare and analyze the docking results with
natural compounds. Compounds S-allyl-L-cysteine, epicatechin gallate and fulvic acid shows high binding affinity i.e. -7.1, -7
and -7, respectively. Epicatechin gallate shows hydrogen bond with Gln156 and Asp35 and fulvic acid shows hydrogen bonding
with Glu27. In case of synthetic compounds tideglusib did not show hydrogen bonding with any amino acid residue of ApoE4
but show high binding affinity of -7.2 same as of natural compound S-allyl-L-cysteine which show high binding affinity of -7.1
but did not show hydrogen bonding with any amino acid residue. Protein-protein interactions of ApoE4 show physical and
functional interaction with related proteins. Our study predict a compound epicatechin gallate on the basis of binding affinity
and hydrogen bonding with amino acid residue as a potential lead compound which may be used as an inhibitor.
asif.rasheed@ciitsahiwal.edu.pkJ Alzheimers Dis Parkinsonism 2018, Volume 8
DOI: 10.4172/2161-0460-C4-046